Swiss government urges voters to back COVID-19 law that foes want to ditch

Published 2021-04-12, 07:05 a/m
© Reuters. Swiss flag on the Mont-Blanc bridge, in Geneva

By John Miller

ZURICH (Reuters) - Switzerland's executive government on Monday urged voters to back the nation's COVID-19 law, which is being challenged by people who fear it eases approval requirements for vaccines and has shifted too much political power away from parliament.

With Switzerland's direct democracy, voters go to the polls on June 13 to weigh in on whether the law to help combat the pandemic went too far. The seven-member executive on Monday agreed at a closed-door session to recommend to voters to back the law.

Switzerland passed the COVID-19 law last September, after concluding rules needed tweaking to react sufficiently to fast-evolving infection numbers and subsequent economic fallout. Among other things, the law governs how financial aid is split among hard-hit businesses and employees who risk losing their livelihoods, without measures to soften the blow.

"The law makes it possible to continue with financial help," the government said in a statement. "More than 100,000 companies and more than a million people have been and are dependent on this financial assistance."

In total, the law covers aid totaling about 35 billion Swiss francs ($38 billion).

Foes, however, contend the law opens the door to an accelerated review of what the campaign calls "hardly tested gene vaccines with long-term effects", leaving the population vulnerable.

Moreover, the group -- calling itself "Friends of the Constitution" -- also said emergency measures meant to combat the pandemic disproportionately shift power away from parliament and toward the Federal Council, Switzerland's executive branch.

"The Federal Council deserves to be taught a lesson," according to the foes' website.

The government on Monday countered their claims, saying while the national law does offer leeway for exceptional drug approvals for people who are severely ill, it does not weaken the vaccine-approval process.

"Vaccines will be approved during the pandemic only after they have been deemed safe," the government said, adding most of the law is due to expire by next year.

© Reuters. Swiss flag on the Mont-Blanc bridge, in Geneva

($1 = 0.9237 Swiss francs)

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.